Amgen Trials On-Body Tepezza for Thyroid Eye Disease
Amgen’s On-Body Injector for Tepezza Succeeds in Thyroid Eye Disease Trial For patients battling the painful and vision-threatening symptoms of Thyroid Eye Disease (TED), the breakthrough drug Tepezza (teprotumumab) has been a game-changer. However, its administration—eight separate 90-minute IV infusions over several months—has been a significant logistical hurdle. Now, a new chapter is beginning. Amgen […]
Amgen Trials On-Body Tepezza for Thyroid Eye Disease Read More »










